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Abstract: The discovery of novel anti-leishmanial compounds remains essential as current treatments
have known limitations and there are insufficient novel compounds in development. We have
investigated three complex and physiologically relevant in vitro assays, including: (i) a media
perfusion based cell culture model, (ii) two 3D cell culture models, and (iii) iPSC derived macrophages
in place of primary macrophages or cell lines, to determine whether they offer improved approaches to
anti-leishmanial drug discovery and development. Using a Leishmania major amastigote-macrophage
assay the activities of standard drugs were investigated to show the effect of changing parameters in
these assays. We determined that drug activity was reduced by media perfusion (EC50 values for
amphotericin B shifted from 54 (51–57) nM in the static system to 70 (61–75) nM under media perfusion;
EC50 values for miltefosine shifted from 12 (11–15)µM in the static system to 30 (26–34)µM under media
perfusion) (mean and 95% confidence intervals), with corresponding reduced drug accumulation
by macrophages. In the 3D cell culture model there was a significant difference in the EC50 values
of amphotericin B but not miltefosine (EC50 values for amphotericin B were 34.9 (31.4–38.6) nM in
the 2D and 52.3 (46.6–58.7) nM in 3D; EC50 values for miltefosine were 5.0 (4.9–5.2) µM in 2D and
5.9 (5.5–6.2) µM in 3D (mean and 95% confidence intervals). Finally, in experiments using iPSC
derived macrophages infected with Leishmania, reported here for the first time, we observed a higher
level of intracellular infection in iPSC derived macrophages compared to the other macrophage
types for four different species of Leishmania studied. For L. major with an initial infection ratio
of 0.5 parasites per host cell the percentage infection level of the macrophages after 72 h was
11.3% ± 1.5%, 46.0% ± 1.4%, 66.4% ± 3.5% and 75.1% ± 2.4% (average ± SD) for the four cells types,
THP1 a human monocytic cell line, mouse bone marrow macrophages (MBMMs), human bone
marrow macrophages (HBMMs) and iPSC derived macrophages respectively. Despite the higher
infection levels, drug activity in iPSC derived macrophages was similar to that in other macrophage
types, for example, amphotericin B EC50 values were 35.9 (33.4–38.5), 33.5 (31.5–36.5), 33.6 (30.5—not
calculated (NC)) and 46.4 (45.8–47.2) nM in iPSC, MBMMs, HBMMs and THP1 cells respectively
(mean and 95% confidence intervals). We conclude that increasing the complexity of cellular assays
does impact upon anti-leishmanial drug activities but not sufficiently to replace the current model
used in HTS/HCS assays in drug discovery programmes. The impact of media perfusion on drug
activities and the use of iPSC macrophages do, however, deserve further investigation.
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1. Introduction
Leishmaniasis is a neglected tropical disease caused by protozoan parasites of 20 different
species of Leishmania. The parasite has two distinct life cycle stages, the motile promastigote,
which is found extracellularly in the gut of the sand fly vector, and the amastigote, an intracellular
stage that survives and divides in the phagolysosomal compartment of macrophages. There are
two main disease manifestations of leishmaniasis, the potentially fatal visceral form (VL) and the
self-curing but disfiguring cutaneous form (CL), which together have an incidence of 1 to 1.5 million
cases in over 100 endemic countries [1–5]. The current drugs for the treatment of both forms of
leishmaniasis have well defined limitations [6,7] and although there are several novel compounds in
development [8,9] (https://www.dndi.org) pipeline, given the known high attrition rates in drug
development, there remains a need for further novel compounds to be added to the pipeline.
Since the early 1980s the in vitro amastigote macrophage model has been the standard assay for
drug discovery [10,11]; this model has provided the basis for high throughput and high content
screening assays to identify novel anti-leishmanial compounds [12,13]. These assays are all based
upon a macrophage monolayer system with exposure to compounds in culture medium for defined
periods at a defined temperature. This basic assay model for anti-leishmanial discovery has not
changed over the past decades in contrast to assays for several other infectious diseases, for example
malaria [14], amoebiasis [15] and tuberculosis [16] where relevant physiological factors or more
appropriate host cells have been used. Our aim was therefore to investigate whether changes in assay
design could expedite the drug discovery process or add to lead identification or lead optimization
stages. Specifically, we determined the influence of: (a) media flow, (b) 3D cell culture models and
(c) use of differentiated human induced pluripotent stem cells (iPSC) as the host cells on the activity of
standard anti-leishmanials.
The biological role that fluid flow plays in physiology has been recognized as significant for many
decades now, whether it is blood flow, media flow or interstitial flow [17]. The perfusion of culture media
in a cell culture system allows for increased nourishment and sustainability of cultures, enables blood
and lymphatic capillary morphogenesis in vitro [18–20], the functional activity of chondrocytes and
osteocytes [21,22], fibroblast differentiation [23] and induction of cytokine production by smooth
muscle cells [24]. Static systems do not offer any form of dynamic chemical or physical stimuli to cells,
such as gradients in chemical concentrations, flow, pressure, or mechanical stress caused by movement
of fluids around them. This is a major limitation in experiments investigating cellular responses
in vitro as the complex interplay of mechanical and biochemical factors is absent [25]. Fluid flow
is also important for drug delivery to cells and can be used to model the permeation of drugs to a
tissue, including chemical gradients or the pulsatile nature of drug delivery [26] and the clearance of
potentially toxic metabolites [27].
2D cell culture systems have been used for in vitro assays to measure infection rates and drug
efficacies against Leishmania parasites since 1975 [28]. In 2D cell culture systems, cells are plated out
into wells and left to settle and attach to a flat surface, spreading and becoming wider and flatter with
a rearrangement of their internal structure to reflect this environment. In contrast, cells found within
tissues have a 3D conformation or assemble into a 3D architecture that can more accurately reproduce
the anatomy or physiology of a tissue for more informative studies [29,30] with, not just an altered
surface area to volume ratio but also changes in cell-cell interactions [31] and receptor presentation [31]
which could affect pathogen invasion [32] and drug/particle/molecule uptake [33].
Over the past decades a wide range of cell types have been used in assays to determine
anti-leishmanial drug activity, from the Sticker’s sarcoma dog fibroblast cell line [28], primary isolated
murine peritoneal macrophages (PEMs) and human monocytes, transformed rodent macrophage
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cell lines [34] and a human monocytic cell line, derived from an acute monocytic leukaemia patient
(THP1) [35], the latter having the advantage of potentially unlimited division and easy maintenance
in high content (HCS) and high throughput screens (HTS). Cell lines have cancer-like properties,
such as immortalisation but also other phenotypes [36]. A disadvantage is that these cells carry
mutations that are responsible for their immortality, making them different from the primary cell that
they represent [37]. Primary isolated cells such as PEMs or mouse bone marrow macrophages and
human monocyte-derived macrophages have been used extensively but only maintain their functional
similarity to macrophage cells within the body for a short period [38] and are not suitable for provision
of the large number of cells required for screening compound libraries. In 2006, Takahashi and
Yamanaka [39] showed that the forced expression of four transcription factors (Oct4, Sox2, Klf4,
and c-Myc) was sufficient to convert fibroblast cells into embryonic stem cell-like cells, induced
pluripotent stem cells (iPSC). Since then a variety of starting cell types, different combinations of
main transcription factors and techniques to deliver the transcription factors into cells have been used
successfully. Many cell types have been derived from iPSCs such as macrophages and cardiomyocytes
but their real utility in drug discovery has not been elucidated.
Here we show how adding complexity to the Leishmania amastigote–macrophage assays alter
responses to standard anti-leishmanial drugs (Table 1) and consider whether this complexity improves
the likely predictivity of the assays. The overall goal would be for these additional layers of complexity
to be integrated into the standard in vitro assay formats to better predict in vivo data.
Table 1. Four standard drugs used in the assays.
Compound Supplier Catalog Number
miltefosine Nycomed, Aldwych, UK Custom
amphotericin B VWR international, Lutterworth, UK E437
paromomycin sulphate Sigma, Gillingham, UK P9297
sodium stibogluconate Sigma, Gillingham, UK S5319
2. Materials and Methods
All materials sourced from Sigma (Sigma Aldrich, Gillingham, Dorset, UK) unless otherwise stated.
2.1. Drugs
The standard drugs used in this study are listed in Table 1.
2.2. Leishmania Parasites
Leishmania major (MHOM/SA/85/JISH118) and Leishmania mexicana (MNYC/BZ/62/M379) amastigotes
were obtained and isolated from BALB/c mouse skin lesions. They were allowed to transform to
promasigotes and were maintained in Schneider’s insect medium supplemented with 10% heat inactivated
foetal calf serum (HiFCS) (Harlan, Bicester, Oxfordshire, UK) at 26 ◦C. Leishmania amazonensis DSRed
(IFLA/BR/1967/PH8) (obtained from Dr Eric Prina, Institut Pasteur, Paris, France) and Leishmania major
mCherry (LV39c5/RHO/SU/59/P) (obtained from Prof Rosa Reguera, University of Léon, Leon, Spain)
were maintained in M199 medium supplemented with 10% HiFCS at 26 ◦C.
The parasites were routinely passaged through BALB/c mice (Charles River, Saffron Walden, UK)
and low passage number promastigotes (below passage number 3) were used for these experiments
due to the loss of infectivity with time of parasite cultivation [40].
All animal work was carried out under a UK Home Office project licence according to the Animal
(Scientific Procedures) Act 1986 and the new European Directive 2012. The Project Licence was reviewed
by an Animal Welfare and Ethical Review Board prior to submission and consequent approval, to the
UK Home Office.
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2.3. Macrophage Types
2.3.1. THP1 Cells
THP1 cells (ATCC, via LGC standards, Teddington, Middlesex, UK) (TIB-202™) were maintained
in RPMI-1640 medium supplemented with l-glutamine and 10% HiFCS. The THP1 cell line was
maintained in an incubator at 37 ◦C and 5% CO2 and passaged to new medium once a week (1/10 v/v
ratio of cells to fresh medium). THP1 cells were differentiated for 24 h at 37 ◦C 5% CO2 from monocyte
to macrophage by the addition of 20 ng/mL Phorbol 12-myristate 13-acetate (PMA).
2.3.2. Mouse Bone Marrow Monocytes
Bone marrow-derived macrophages (BMM) were obtained from femurs of female BALB/c mice
(Charles River Ltd., Saffron Walden, Essex, UK). A 25 g needle was used to flush the bone cavity with
5 mL of ice-cold Dulbecco’s modified Eagles medium (DMEM). Flushed DMEM was collected and
then centrifuged before re-suspending the bone marrow progenitor cells in RPMI 1640 + 10% HiFCS
and penicillin/streptomycin (pen/strep).
The mouse bone marrow monocytes were plated at a concentration of 25 million cells per T175
flask. Then extra RPMI + 10% HiFCS and penicillin/streptomycin containing macrophage colony
stimulating factor (m-CSF) was added to give a final concentration of 50 ng/mL of m-CSF. The cells
were incubated for 7 days in a 37 ◦C incubator before mature macrophages were harvested.
2.3.3. Human Bone Marrow Monocytes
Human bone marrow mononuclear cells from a single donor were purchased from the American
Type Culture Collection (ATCC, VIA LGC standards, Teddington, Middlesex, UK) (PCS-800_013).
25 million cells were delivered cryopreserved, these were defrosted and plated. All experiments were
conducted on the same batch of cells. The ATCC have characterised these cells to be CD45, CD3, CD8,
CD58, CD14, CD19 and CD34 positive immediately before freezing.
All of the human bone marrow monocytes were plated in a T175 flask in RPMI 1640 + 10% HiFCS,
pen/strep and 50 ng/mL m-CSF. The cells were incubated for 7 days in a 37 ◦C incubator before mature
macrophages were harvested.
2.3.4. iPSC Cells
The human iPSC lines used in this study, Kolf2, were generated by the Sanger Institute’s Human
Induced Pluripotent Stem Cells Initiative (HipSci) project and can be purchased via Public Health
England/ECACC (HPSI0114i-kolf_2, catalogue number 77650100). To differentiate human iPSCs
into macrophages, we used the approach of Hale et al. [41]. Briefly, a subclone of undifferentiated
human iPSCs Kolf2 C1 were grown from frozen vials, initially feeder-free on gelatin coated plates in
TESR-E8 medium and then on mitotically inactivated mouse embryonic fibroblast (MEF) monolayers.
Once grown to confluence the cells were collected and transferred into iPSC base medium (Advanced
DMEM/F12 supplemented with 20% KnockOut Serum Replacement, 2 mM L-Glutamine, 0.055 mM
β-mercaptoethanol) in 10cm2 bacterial petri dishes for 4 days to generate Embryoid Bodies (EBs).
On Day 5, the ball-like EBs were transferred back into 10cm2 tissue culture dishes that had been
pre-coated with gelatin. Myeloid precursor cells were generated in the presence of 25 ng/mL IL-3
(R&D, now Bio-techne, Abingdon, Oxfordshire, UK) and 50 ng/mL m-CSF (R&D) followed by terminal
differentiation and maturation of myeloid precursors into matured macrophages in the presence of
m-CSF (1000 ng/mL).
2.3.5. Mouse Peritoneal Macrophages (PEMs)
Mouse peritoneal macrophages were isolated from female CD1 mice 24 h after peritoneal injection
with 0.5 mL of 2% starch solution in sterile water. Macrophages were collected by abdominal lavage
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with cold RPMI-1640 medium containing 1% penicillin and streptomycin. The collected cells were
centrifuged for 15 min at 500 g and 4 ◦C, washed in RPMI-1640 medium and re-suspended in RPMI-1640
medium containing 10% HiFCS.
2.4. Effect of Perfusion of Culture Medium on Anti-Leishmanial Activity of Drugs
The influence of perfusion of the culture medium on the infection levels of Leishmania was
investigated using the QV900 media perfusion system (Kirkstall LTD, York, UK) developed and
detailed in elsewhere [42]. The method for the static infection of PEMs seeded on 12 mm glass cover
slips and their transfer to the QV900 is also described in O’Keeffe et al. [42]. Briefly, PEMS are seeded
onto glass coverslips and infected with promastigotes in static conditions for 24 h. Subsequently two
thirds of the glass coverslips containing infected macrophages were transferred to the media perfusion
system and maintained under flow conditions either at the bottom of the well or on top of an insert, at a
flow speed of 360 µL/min for 72 h in a 34 ◦C, 5% CO2 incubator. The remaining coverslips were used for
the static control, with macrophages maintained in the same culture medium without flow. This creates
three different culture media flow rates, (i) static (0 m/s), (ii) low flow (1.45 × 10−9 m/s; cells placed
at bottom of well) and (iii) high flow (1.23 × 10−7 m/s; cells placed on top of inserts) [42]. After the
initial 24 h of static infection, the media used for the activity of drug studies was supplemented
with drug (miltefosine at 20 µM, 5 µM or 1.25 µM, amphotericin B (AmB) at 200 nM, 50 nM or
12.5 nM, sodium stibogluconate at 600 µg, 200 µg or 60 µg of SbV/mL or paromomycin sulphate salt at
300 µM, 100 µM or 30 µM). After 72 h, all coverslips were removed from the wells, methanol-fixed and
Giemsa stained, and microscopically examined (400× magnification) to count the number of infected
macrophages and thereby measure the drug-induced reduction in parasite infection of the host cell.
Non-linear sigmoidal curve fitting (variable slope) was conducted using Prism Software (GraphPad,
Surrey, UK).
2.5. Effect of Perfusion of Culture Medium on Drug Accumulation by Infected Macrophages
Experiments were conducted as described in the previous section, except for the drug
concentrations and time points used. In these experiments, miltefosine at 20 µM or AmB at 1 µM
were added to each well. Cultures were maintained for 4, 8, 12 or 24 h at 34 ◦C and 5% CO2,
after which coverslips were transferred to a new 24 well plate and washed three times with cold
PBS. Drug extraction methods were followed from Voak et al. [43]. When miltefosine was used,
a back-exchange step was conducted by adding 500 µL of 3% (w/v) fatty acid-free BSA in PBS to remove
any membrane-bound miltefosine, and then washing the cells again with PBS. Subsequently, the cells
were lysed by the addition of 0.1% (v/v) formic acid in water to each well, and vigorous mixing by
pipetting up and down every five minutes during a 30 min incubation at room temperature.
Lysates were transferred to a microcentrifuge tube with 250 µL acetonitrile with tolbutamide
(200 ng/mL). When amphotericin B was used, cells were lysed (as described for miltefosine), and lysates
were transferred to a microcentrifuge tube with 250 µL of 16% DMSO in methanol with tolbutamide
(200 ng/mL). Tolbutamide was used as an internal standard for both drugs. Microcentrifuge tubes
containing the internal standard and miltefosine or amphotericin B were placed on a shaker for 10 min
before being centrifuged for 15 min at 4150 g at 4 ◦C. 200 µL of the supernatant was transferred into
96 well plates and stored at −80 ◦C. A calibration curve was created using untreated cell lysates spiked
with known miltefosine or amphotericin B concentrations. A further set of blanks were prepared
without tolbutamide [43].
Drug concentrations were determined by Pharmidex Ltd., a company specialising in ADMET
assays with experience in miltefosine and amphotericin B drug accumulation in cell studies [43] using
HPLC-MS-MS with electro-spray ionisation on an Agilent 1200 HPLC/Agilent 6410 triple quad under
positive ion MS-MS mode. Data were extracted into Excel files and analysed in both Excel and Prism.
The remaining lysate was used to measure protein concentration as a measure of cell number using a
Pierce™ BCA protein assay kit (Thermo Scientific, Loughborough, UK).
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2.6. 3D Cell Culture Experiments
2.6.1. 3D Cell Seeding Protocols
Alvetex scaffolds (24 well sized spun polystyrene scaffolds (ReproCELL Europe Ltd.,
Stockton-on-Tees, UK) were submerged in 70% ethanol for 10 s, and then washed in RPMI-1640.
Both Invitrocue (3D CelluSponge, Invitrocue Ltd., Singapore 138667, Singapore) and Alvetex Scaffolds
were then placed in a 24 well plate. PEMs were washed, centrifuged and re-suspended at 4 × 107 per mL
in RPMI-1640 supplemented with 10% HiFCS. Cells were seeded into Invitrocue or Alvetex scaffolds
by pipetting 25 µL of cell suspension directly on to the scaffold (as specified by Invitrocue for the
CelluSponge). Scaffolds were maintained at 37 ◦C and 5% CO2 for 45 min, after which the wells were
topped up with 500 µL of RPMI-1640 supplemented with 10% HiFCS and replaced in the incubator
for 24 h.
2.6.2. Infection by Leishmania in 3D Cultures
The adhered PEMs in the 3D scaffolds were infected with stationary phase promastigotes, at a
range of parasite: peritoneal macrophage ratios (0.5:1 to 6:1). The scaffolds were maintained at 34 ◦C and
5% CO2 for a further 72 h, after which they were fixed in 4% paraformaldehyde (PFA) overnight at 4 ◦C.
After 24 h, the scaffolds were treated with 0.2% Triton X-100 in PBS for 10 min and then 1% BSA in PBS
for 10 min. Scaffolds were then stained with phalloidin Cruz fluor Actin labelling antibody (Santa Cruz
Biotechnology, Heidelberg, Germany) at 4 ◦C on a plate shaker for 24 h, after which they were washed
and treated with 300 mM DAPI stain for 10 min. The scaffolds were examined using a Zeiss LSM510
confocal microscope (40× magnification) (Zeiss, Germany) and the number of macrophages that were
infected (out of a total of 100 macrophages) were counted to determine the percentage infection.
Images taken during the course of the experiments were analysed computationally both at Invitrocue
(using the ImarisCell module of Imaris 8.2.0 (Oxford Instruments-Bitplane AG, Zurich, Switzerland))
and at LSHTM (using the Volocity software, Quorum Technologies, https://quorumtechnologies.com/),
to produce values for percentage infection and the number of parasites per cell.
2.6.3. Drug Activity in 3D Infection Models
The adhered PEMs in the Invitrocue scaffold were infected with stationary phase promastigotes
at a ratio of 5 L. major (mCherry) promastigotes or 7 L. amazonensis (DSred2) to 1 macrophage and
maintained at 34 ◦C in a 5% CO2 for 24 h. After 24 h, media was removed from all wells and miltefosine
at concentrations of 20 µM, 5 µM and 1.25 µM or amphotericin B at concentrations of 200 nM,
50 nM and 12.5 nM were added in triplicates. A set of drug-free controls were included in triplicate,
by adding culture media. After 72 h, percentage infection of PEMs was assessed as described above.
This percentage infection was then scaled in comparison to the untreated and uninfected controls.
2.7. Influence of Host Cell Type on Infection by Parasite
To investigate the potential of iPSC cells we first compared infection levels in macrophages of
different origin, namely THP1, human and MBMM and iPSC derived macrophages within standard
static 2D assays. The cells were seeded in 16-well Lab-Tek™ plates (Thermofisher, Paisley, UK) in
RPMI-1640 supplemented with 10% HiFCS at a density of 2 × 104 per well. After 24 h incubation at
37 ◦C and 5% CO2, cells were infected with stationary phase promastigotes (L. major JISH 118, L. major
mCherry, L. mexicana M379 and L. amazonensis DSred2) at a range of parasite: host cell ratios (0.5:1 to
10:1) and cells were maintained at 34 ◦C in a 5% CO2. After 24 h, the culture medium was replaced to
remove extracellular promastigotes and one slide was fixed with methanol and stained with Giemsa
to determine the initial level of infection. Infection of host cells was determined microscopically
(400× magnification) by counting the number of macrophages that were infected and the number of
amastigotes per host cell (out of a total of 100 macrophages).
Microorganisms 2020, 8, 831 7 of 22
In cultures with a sufficient level of infection, (i.e., >50% of macrophages being infected after
24 h) a drug (miltefosine at 20 µM, 5 µM or 1.25 µM, amphotericin B at 200 nM, 50 nM or 12.5 nM,
sodium stibogluconate at 600 µg, 200 µg or 60 µg of SbV/mL, paromomycin sulphate salt at 300 µM,
100 µM or 30 µM) was added (in triplicate on the same plate) and incubation was continued for a further
72 h. All slides were methanol-fixed, Giemsa stained, and microscopically examined (400× magnification)
to count the number of macrophages that were infected (out of a total of 100 macrophages) and
thereby measure the drug-induced reduction in parasite infection of the PEMs. The average number of
amastigotes per peritoneal macrophage were also counted.
2.8. Statistical Analysis
All statistical analysis was performed using Graphical Prism Vs7 (Graphpad, San Diego, CA, USA).
3. Results
3.1. The Influence of Culture Media Perfusion on Anti-Leishmanial Drug Activity
The activities of amphotericin B (Figure 1a), miltefosine (Figure 1b), paromomycin sulphate
(Figure 1c) and sodium stibogluconate (Figure 1d) in the PEM–L. major amastigote model were
determined at three different culture media flow rates, (i) static (0 m/s), (ii) low flow (1.45 × 10−9 m/s;
cells placed at bottom of well) and (iii) high flow (1.23 × 10−7 m/s; cells placed on top of inserts) [42].
EC50 and all measurable EC90 values were altered by varying amounts as the speed of media perfusion
was increased (Table 2). However, no significance was determined between the EC50 or EC90 values of
any of the drugs, except for a significant change in the EC50 of miltefosine between the static and low
flow conditions (one way ANOVA p < 0.05). The difference by which the EC50 values increased when
higher media flow rates were applied is small relative to the larger differences noted between the EC90
values of amphotericin B and sodium stibogluconate. Both miltefosine and paromomycin showed
increases in the EC50 value with a changed flow rate. The increase in media perfusion rates affected
the Hill slopes of the dose response curve impacting more on the EC90 values compared with other
measurements of compound potency.
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Figure 1. Dose-response curves showing the reduction in infection of mouse peritoneal macrophages 
(PEMs) caused by amphotericin B (a), miltefosine (b), paromomycin (c) and sodium stibogluconate 
(d) with a variable slope and minimum and maximum set to 0 and 100% respectively. Infection was 
measured by manual counting using a microscope and the drug-induced percentage reduction of 
infection was calculated in comparison to untreated controls. Three different experimental conditions 
resulting in three different media perfusion speeds were used: static (0 m/s), low flow (1.45 × 10−9 m/s) 
and high flow (1.23 × 10−7 m/s). n = 9. Error bars show SD. 
Table 2. EC50 and EC90 values of the four drugs under three different conditions of culture 
media flow. Mean and 95% confidence intervals are shown. NC = Not calculated. 
Condition 
Static Low Flow High Flow 
EC50 EC90 EC50 EC90 EC50 EC90 
Amphotericin B (nM) 54 (51–57) 124 (100–150) 63 (52–67) 196 (114–244) 70 (61–75) 273 (185–305) 
Miltefosine (µM) 12 (11–15) NC 21 (18–23) NC 30 (26–34) NC 
Paromomycin (µM) 85 (64–111) NC 198 (162–254) NC 188 (158–230) NC 
SbV (µg/mL) 223 (220–237) 368 (350–465) 228 (214–242) 532 (436–535) 212 (193–233) 709 (572–892) 
3.2. Effect of Culture Media Flow on Drug Accumulation by Peritoneal Macrophages 
To investigate why media perfusion altered the EC50 and EC90 values, we measured the 
accumulation of amphotericin B and miltefosine by infected PEMs. Drug accumulation by the cells 
exposed to different culture media flow conditions was different as shown in Figure 2. When 
comparing amphotericin B drug accumulation between low and high flow conditions a statistical 
difference is observed (p < 0.05 one way ANOVA). A time-dependent and media perfusion-
dependent effect could be observed for both drugs, accumulation being significantly higher in the 
static system relative to the media perfusion systems, after 24 h (Tables 3 and 4). 
Figure 1. Dose-response curves sho i t ti i infection of mouse peritoneal macrophages
(PEMs) caused by amphotericin B (a), miltef si e ( ), r o ycin (c) and sodium stibogluconate
(d) with a variable slope and minimu and axi u set to 0 and 100% respectively. Infection was
measured by manual counting using a icroscope and the drug-induced percentage reduction of
infection was calculated in comparison to untreated controls. Three different experimental conditions
resulting in three different media perfusion speeds were used: static (0 m/s), low flow (1.45 × 10−9 m/s)
and high flow (1.23 × 10−7 m/s). n = 9. Error bars show SD.
Table 2. EC50 and EC90 values of the four drugs under three different conditions of culture media flow.
Mean and 95% confidence intervals are shown. NC = Not calculated.
Condition
Static l High Flow
EC50 EC90 EC50 EC90 EC50 EC90
Amphotericin B (nM) 54 (51–57) 124 (100–150) 63 (52–67) 196 (114–244) 70 (61–75) 273 (185–305)
Miltefosine (µM) 12 (11–15) NC 21 (18–23) NC 30 (26–34) NC
Paromomycin (µM) 85 (64–111) NC 198 (162–254) NC 188 (158–230) NC
SbV (µg/mL) 223 (220–237) 368 (350–465) 228 (214–242) 532 (436–535) 212 (193–233) 709 (572–892)
3.2. Effect of Culture Media Flow on Drug Accumulation by Peritoneal Macrophages
To investigate why media perfusion altered the EC50 and EC90 values, we measured the
accumulation of amphotericin B and miltefosine by infected PEMs. Drug accumulation by the cells
exposed to different culture media flow conditions was different as shown in Figure 2. When comparing
amphotericin B drug accumulation between low and high flow conditions a statistical difference is
observed (p < 0.05 one way ANOVA). A time-dependent and media perfusion-dependent effect could
be observed for both drugs, accumulation being significantly higher in the static system relative to the
media perfusion systems, after 24 h (Tables 3 and 4).
Table 3. Concentrations of amphotericin B in infected PEMs (ng/µg of protein) maintained at the three
different speeds of media perfusion. Means and 95% confidence intervals are shown.
Time (h)
ng of Drug Per µg of Protein in Cell Lysates
Static Low Flow High Flow
0 nm/s 1.45 ± 0.01 nm/s 123 ± 0.001 nm/s
4 0.68 (0.57–0.80) 0.80 (0.61–1.00) 0.62 (0.46–0.77)
8 1.10 (0.86–1.34) 1.66 (1.20–2.13) 1.19 (0.80–1.59)
12 1.56 (1.31–1.81) 1.28 (1.11–1.46) 0.96 (0.82–1.10)
24 2.56 (1.63–3.48) 1.83 (1.32–2.33) 1.56 (1.19–1.94)
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Table 4. Concentrations of miltefosine in infected PEMs (ng/µg of protein) maintained at the three
different speeds of media perfusion. Means and 95% confidence intervals are shown.
Time (h)
ng of Drug Per µg of Protein in Cell Lysates
Static Low Flow High Flow
0nm/s 1.45 ± 0.01 nm/s 123 ± 0.001 nm/s
4 12.3 (12.5–12.1) 11.3 (10.9–11.6) 10.4 (9.9–10.9)
8 15.0 (14.7–15.3) 15.1 (14.4–15.7) 11.9 (11.2–12.5)
12 16.6 (16.4–16.7) 14.2 (14.1–14.4) 14.4 (14.1–14.9)
24 20.6 (19.6–21.5) 15.9 (15.9–15.9) 14.4 (13.9–15.0)
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Figure 2. Accumulation of amphotericin B (left) and miltefosine (right) over time in PEMs maintained
either in static condition or in the QV900 media perfusion system Three different experimental conditions
res lting in three different media p rfusion speeds were used: static (0 m/s), low flow (1.45 × 10−9 m/s)
and high flow (1.23 × 10−7 m/s). n = 9, Error bars show SD.
Accu ulation of amphotericin B (AmB) increased over time (Figure 2) (Tables 3 and 4),
with the highest concentration of AmB within PEMs maintained in the static system seen after
24 h. Comparing this value, a reduced accumulation under low culture media flow (p < 0.001 two-way
ANOVA) can be observed and a further reduction in accumulation under high culture media flow
c nditio s ( wo-way ANOVA, p < 0.0001) is also seen. The intracellular concentrations of miltefosine
also increased over time (Figure 2). By 24 h, the static system showed the highest a cumulation of drug
c mpared to the low flow media assay (p < 0.01, two-way ANOVA), and th high media flow a say
(p < 0.001, two-way ANOVA). Both data sets show hat, th cells maintained under flow conditions
have reduced rug accumulation compared to the static culture I.e., higher the flow speed of the media
over the surface of the cells, the lower the drug ccumulation.
3.3. Formation of 3D Structures
Cells plated in the Alvetex scaffold (Figure 3a) settled throughout the scaffold forming 3D
connections to the scaffold itself. However, the cells did not form any secondary structure remaining
isolated and not in a multicellular complex. In comparison the cells that were plated in the Invitrocue
scaffold (Figure 3b) settled into the pores of the scaffold and formed a secondary multicellular structure.
Using the descriptions of the different forms that cells take as a secondary structure in 3D cell culture
from Kenny et al. [44], we suggest the secondary structure the cells in the Invitrocue scaffold resembles
a grape-like structure.
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Figure 4. Box and whisker plots showing the infection rates of L. major (left) and L. amazonensis (right)
in 2D (n = 6) or 3D (n = 6) cell cultures, using Invitrocu or Alvetex sc ffolds. Infection ratio = Parasites:
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3.5. Influence of 3D Cell Culture Set-Up on Anti-Leishmanial Drug Activity
Activities of AmB and of miltefosine were determined against the two fluorescent parasite strains,
L. amazonensis DSRed2 and L. major mCherry. The proportion of infected PEMs as well as the number of
parasites per macrophage (Figures 5–8) at each drug concentration were counted and used to calculate
activity. The EC50 values for the experiments using L. major and L. amazonensis are summarised in
Tables 5 and 6 respectively. Volocity refers to automated counting of images utilising the software
package of the same name. Computer counting refers to automated counting of images using the
ImarisCell module of Imaris 8.2.0.
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Figure 5. (Left) Dose-response curves for 2D (n = 6) and 3D (n = 6) cell cultures showing the reduction in
percentage infection of PEMs by L. major produced by treatment using amphotericin B. The percentage
reduction in infection calculated based on total infection seen in the untreated controls in either
condition. (Right) Reduction in L. major parasite burden of PEMs for 2D (n = 6) and 3D (n = 6) cell
cultures, produced by dosing with amphotericin B. Error bars show standard deviation.
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Figure 6. (Left) Dose-response curves for 2D (n = 6) and 3D (n = 6) cell cultures showing the reduction
in percentage infection of PEMs by L. major produced by treatment using miltefosine. The percentage
reduction in infection calculated based on total infection seen in the untreated controls in either
condition. (Right) Reduction in L. major parasite burden of PEMs for 2D (n = 6) and 3D (n = 6) cell
culture, produced by dosing with miltefosine. Error bars show SD.
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Figure 7. (Left) Dose-response curves for 2D (n = 6) and 3D (n = 6) cell culture showing the reduction
in percentage infection of PEMs with L. amazonensis produced by treatment using amphotericin B.
The percentage reduction in infection calculated based on total infection seen in the untreated controls
in either condition. (Right) Reduction in L. amazonensis parasite burden of PEMs for 2D (n = 6) and 3D
(n = 6) cell culture, produced by exposure to amphotericin B. Error bars show standard deviation.
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Table 5. EC50 values of amphotericin B and miltefosine against L. major mCherry 
amastigotes in PEMs, in 2D or 3D cell culture. Means and 95% confidence intervals are 
shown. 
 EC50 
 3D 2D 
 Volocity Counting Computer Counting Manual 
Amphotericin B (nM) 52.3 (46.6–58.7) 76.2 (37.7–203.5) 34.9 (31.4–38.6) 
Miltefosine (µM) 5.85 (5.52–6.21) 6.90 (4.09–12.22) 5.02 (4.88–5.16) 
Table 6. EC50 values of amphotericin B and miltefosine against L. amazonensis amastigotes 
in PEMs, in 2D or 3D cell culture. Means and 95% confidence intervals are shown. 
 EC50 
 3D 2D 
 Volocity Counting Computer Counting Manual 
Amphotericin B (nM) 46.7 (41.5–52.3) 63.5 (36.1–117.0) 68.0 (65.3–70.8) 
Miltefosine (µM) 19.8 (16.2–25.9) 21.4 (17.4–28.7) 47.6 (37.2–66.8) 
Dose response relationships were determined by both methods and both showed equivalent 
reduction of infections in the 3D and 2D cultures for both L. major and L. amazonensis. The only 
Figure 8. (Left) Dose-response curves for 2D (n = 6) and 3D (n = 6) cell culture showing the reduction in
percentage infection of PEMs with L. amazonensis produced by dosing with miltefosine. The percentage
reduction in infection calculated based on total infection seen in the untreated controls in either
condition. (Right) Reduction in L. amazonensis parasite burden of PEMs for 2D (n = 6) and 3D (n = 6)
cell culture, produced by dosing with miltefosine. Error bars show standard deviation.
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Table 5. EC50 values of amphotericin B and miltefosine against L. major mCherry amastigotes in PEMs,
in 2D or 3D cell culture. Means and 95% confidence intervals are shown.
EC50
3D 2D
Volocity Counting Computer Counting Manual
Amphotericin B (nM) 52.3 (46.6–58.7) 76.2 (37.7–203.5) 34.9 (31.4–38.6)
Miltefosine (µM) 5.85 (5.52–6.21) 6.90 (4.09–12.22) 5.02 (4.88–5.16)
Table 6. EC50 values of amphotericin B and miltefosine against L. amazonensis amastigotes in PEMs,
in 2D or 3D cell culture. Means and 95% confidence intervals are shown.
EC50
3D 2D
Volocity Counting Computer Counting Manual
Amphotericin B (nM) 46.7 (41.5–52.3) 63.5 (36.1–117.0) 68.0 (65.3–70.8)
Miltefosine (µM) 19.8 (16.2–25.9) 21.4 (17.4–28.7) 47.6 (37.2–66.8)
Dose response relationships were determined by both methods and both showed equivalent
reduction of infections in the 3D and 2D cultures for both L. major and L. amazonensis. The only
significant difference noted with amphotericin B was between the 3D assay counted with the Volocity
method and the 2D manual counting (ANOVA one-way p < 0.05). When using miltefosine no statistical
difference was seen for L. major between any of the counting methods (p > 0.05). Similarly, when using
amphotericin B on L. amazonensis infected cells, no significant difference was seen between the values
produced by any of the counting methods (p > 0.05). A significant difference was seen between the
two different methods of automated counting (ImarisCell 8.2.0 referred to as computer counting and
Volocity), which had been used to analyse the 3D images taken over the course of the experiments,
when comparing the values produced for miltefosine against L. amazonensis (ANOVA, p < 0.05).
Similarly, when the number of parasites per peritoneal macrophages is considered, there was no
significant difference between the 3D and the 2D cell culture systems, and similar reductions in parasites
per peritoneal macrophages were achieved by the two drugs for both L. major and L. amazonensis
(two-way ANOVA, p < 0.05).
3.5.1. Evaluation of the Infection Potential in iPSC Macrophages
When investigating the potential of iPSC derived macrophages as a host cell for Leishmania
parasites, we initially determined Leishmania infection rates in the iPSC macrophages in comparison to
other types of macrophage that are commonly used (THP1, HBMM and MBMM) to ensure there were
comparable levels of infection established. Four Leishmania species, at a range of parasite to host cell
ratios, were used in this study to determine if % host cell infection of iPSC derived macrophages were
equal utilising different Leishmania species (Figure 9).
THP1 cells consistently showed the lowest Leishmania percentage infection rates (Figure 9).
In contrast, iPSC derived macrophages showed the highest infection rates, especially at the lower
parasite: host cell ratios, for both L. major JISH and L. amazonensis. MBMM and HBMM showed similar
infection rates with L. major JISH and L. amazonensis. However, MBMM showed higher infection rates
for L. mexicana compared to HBMM and the opposite was seen for L. major mCherry, where HBMM
showed higher infection rates compared to MBMM. Overall, we show that all four species of Leishmania
established high levels of infection in iPSC macrophages.
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Figure 9. Percentage infections of L. major JISH (a), L. major mCherry (b), L. amazonensis (c) 
and L. mexicana (d) after 72 h incubation in each of the four cell types. n = 9. Line is drawn 
at 80% infection. Error bars show minimum and maximum values. 
Fi . Per e i fections of L. major JISH (a), L. major mCherry (b), L. am zonensis (c) and
L. mexicana (d) after 72 h incubatio in each of the four cell types. n = 9. Line is drawn at 80% infection.
Error bars show minimum and maxi um values.
3.5.2. Evaluation of Anti-Leishmanial Drug Activity in iPSC Derived Macrophages
Initially we established the parasite: host cell ratio that caused a percentage infection of more
than 80% after 72 h in the untreated controls (Table 7). This ratio differed for each parasite strain
and cell type and the ratio shown in the table was subsequently used to infect the different cell types
(iPSC derived macrophages, HBMM and MBMM and THP1 cells). After 24 h, the infection was
measured to check that the infection was established (Table 8). Then the infected host cells were
exposed to a range of concentrations of amphotericin B, miltefosine and sodium stibogluconate (SbV)
for 72 h. Dose responses were determined (see Supplementary Figures S1–S3) and from these, EC50 and
EC90 values were determined (Tables 9–11).
Table 7. Optimal initial infection ratio for each parasite strain for each of the four different cell
types used.
THP1 MBMM HBMM iPSC
L. major JISH 5:1 3:1 3:1 1:1
L. major mCherry 5:1 5:1 2:1 2:1
L. amazonensis dsRed 10:1 7:1 7:1 3:1
L. mexicana 7:1 1:1 5:1 2:1
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Table 8. The initial infection after 24 h for each parasite strain for each of the four different cell
types used.
% Infection Levels after 24 h
THP1 MBMM HBMM iPSC
L. major JISH 30 ± 1 55 ± 2 37 ± 6 27 ± 2
L. major mCherry 27 ± 4 59 ± 4 32 ± 2 42 ± 1
L. amazonensis dsRed 41 ± 4 60 ± 1 70 ± 1 52 ± 1
L. mexicana 45 ± 4 26 ± 2 68 ± 7 69 ± 1
Table 9. EC50 and EC90 values of amphotericin B (nM) against the different parasites in different host
cell types. Means and 95% confidence intervals are shown.
iPSC THP1 MBMM HBMM
L. major JISH EC50 nM 35.9 (33.4–38.5) 46.4 (45.8–47.2) 33.5 (31.5–36.5) 33.6 (30.5–NC)
EC90 nM 105.2 (94.2–117.5) 70.5 (66.1–74.2) 62.9 (59.8–65.9) 54.4 (NC–57.0)
L. major mCherry EC50 nM 70.7 (68.4–73.2) 69.0 (67.7–69.7) 44.1 (42.2–45.7) 38.2 (36.3–40.1)
EC90 nM 182.0 (165.6–202.0) 102.5 (100.0–105.0) 85.0 (77.3–93.0) 78.5 (72.9–84.1)
L. amazonensis dsRed
EC50 nM 79.8 (77.6–82.0) 63.4 (61.0–64.6) 60.9 (57.5–64.3) 51.1 (46.9–55.4)
EC90 nM 229.2 (213.3–247.0) 159.3 (148.5–171.7) 251.6 (222.3–286.6) 188.8 (159.7–226.0)
L. mexicana
EC50 nM 59.8 (58.2–61.3) 76.5 (75.1–78.1) 55.4 (54.0–56.9) 67.8 (65.3–70.3)
EC90 nM 102.4 (95.9–109.4) 144.6 (139.0–150.9) 109.2 (102.0–117.2) 131.5 (121.4–143.6)
Table 10. EC50 and EC90 values of miltefosine (µM) against the different parasites in different host cell
types. Means and 95% confidence intervals are shown.
iPSC THP1 MBMM HBMM
L. major JISH EC50 µM 5.8 (5.2–6.5) 7.7 (7.5–8.1) 6.4 (6.1–6.7) 7.4 (6.9–8.0)
EC90 µM NC 17.7 (16.5–19.2) 19.2 (17.4–21.4) 34.2 (28.5–41.4)
L. major mCherry EC50 µM 15.3 (14.2–16.4) 9.4 (8.5–10.3) 14.9 (12.2–16.9) 4.9 (4.1–5.7)
EC90 µM NC NC NC 16.1 (11.3–23.9)
L. amazonensis dsRed
EC50 µM 76.6 (64.2–94.9) 28.2 (26.6–30.0) 25.3 (23.5–27.4) 14.3 (13.3–15.4)
EC90 µM NC NC NC 62.2 (52.2–75.6)
L. mexicana
EC50 µM 5.3 (5.0–5.5) 4.9 (4.6–5.1) 5.0 (4.7–5.3) 6.0 (5.3–6.8)
EC90 µM 17.2 (15.6–18.9) 15.6 (13.9–17.6) NC 25.1 (19.7–33.0)
Table 11. EC50 and EC90 values of sodium stibogluconate (ugSbV/mL) against the different parasites in
different host cell types. Means and 95% confidence intervals are shown.
iPSC THP1 MBMM HBMM
L. major JISH EC50 µgSb
V/mL 355 (308–415) 186 (178–193) 2770 (2017–4146) 348 (324–375)
EC90 µgSbV/mL NC NC NC NC
L. major mCherry EC50 µgSb
V/mL 220 (209–232) 253 (234–274) 730 (686–787) 434 (397–477)
EC90 µgSbV/mL NC NC NC NC
L. amazonensis dsRed
EC50 µgSbV/mL 306 (266–352) 459 (442–477) 503 (485–524) 255 (238–273)
EC90 µgSbV/mL NC NC NC NC
L. mexicana
EC50 µgSbV/mL 347 (328–366) 1840 (1481–2411) 435 (406–465) 299 (268–332)
EC90 µgSbV/mL NC NC NC NC
The EC50 values for amphotericin B were similar in all cell types (Tables 9–11). EC50 values for
miltefosine were similar for L. major JISH or L. mexicana infections. However, for L. major mCherry
responses are more variable and miltefosine proved less effective against L. amazonensis. EC50 values for
sodium stibogluconate were similar between cell types with a couple of outliers (p < 0.01). In MBMM
high EC50 values were determined for sodium stibogluconate on L. major JISH or L. major mCherry
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infections. THP1 cells infected with L. mexicana parasites and treated with sodium stibogluconate also
gave a higher than average EC50. iPSC derived macrophage values were mostly similar to hBMM.
4. Discussion
Over the past decade anti-leishmanial drug discovery has been significantly enhanced by the
screening of compound libraries against intracellular Leishmania amastigotes mainly in HCS assays,
with over 4 million compounds now tested [45], many hits identified and several novel candidates
in pre-clinical and clinical development. In vitro assays also have a key role in lead identification,
lead optimization and the determination of structure activity relationships (SARs). We have focussed
on the development of more complex in vitro assays, based upon a standard amastigote-macrophage
model, to investigate whether any offer suitable alternatives for the more demanding studies to
differentiate hits and leads. In other disease areas both microfluidics and tissue engineering have
been used to adapt assays for potency and PK-PD studies, for example 3D models in cancer cell drug
sensitivity [46,47] and in cytotoxicity assays [48]. Microfluidics and flow have been used to analyse
PK/PD relationships of antibacterial [49] and antimalarial [26] compounds. Recently, both 3D and
media perfusion were used to model drug combinations against M. tuberculosis in a hollow fibre
bioreactor model [50]. None of these methodologies have so far been used to explore the drug activities
of anti-leishmanial compounds, which still utilise models and approaches that were established over
30 years ago [51]. The primary functions of in vitro models are to identify compounds with potency
and selectivity, to provide structure activity relationship data and to ensure that promising compounds
progress to in vivo studies.
4.1. Influence of Culture Media Flow on Drug Activity
All four standard anti-leishmanial compounds (amphotericin B, miltefosine, paromomycin sulphate
and sodium stibogluconate) showed varying levels of activity in static, slow culture medium perfusion
and faster perfusion assays, but with a pattern of greater potency in static assays compared to media
flow. This pattern is not obvious when comparing EC50 values which are similar. However, the shift
is larger but still not significant (p > 0.05) when comparing EC90 values which increase with the
rate of media perfusion. This reflects changes in the Hill slope, in that the faster the flow the less
steep the Hill slope is, suggesting that the higher the flow the less competition for receptor binding
is present, reducing the Hill co-efficient closer to 1 which is a sign of 1:1 binding without any other
intervention. A higher Hill slope is often a sign of multiple molecules binding to the same target,
in this case the compound to the parasite. For anti-infectives, the EC90 values of compounds are
more important as the ultimate aim is to eliminate the infection from tissues. Of the several possible
explanations for the reduced activity, from cell metabolic rates to oxygen tension [52] we investigated
only the change in drug accumulation by macrophages under the different media perfusion rates.
This demonstrated a significantly lower accumulation of the two drugs studied, amphotericin B and
miltefosine, by infected PEMs at high fluid speeds. We did not determine whether this was driven
mainly by the host cell or intracellular parasites. Media perfusion could affect the binding of the drug
molecules to their receptors through either a reduction in contact time over the surface area or by
lowering the probability of molecules coming in contact with the surface receptors that lead to uptake
into the cell by endocytosis. Both amphotericin B and miltefosine are highly protein bound [53] and
therefore endocytosis mechanisms are also important. Previously [42] we have shown that the media
perfusion system created zones of re-circulation that could lead to a localized lower drug concentration.
4.2. Influence of 3D on Cell Culture Infection and Drug Activity
Initially, we sought to establish which of two scaffolds selected was capable of establishing an
infection suitable for drug studies. Based upon percentage macrophage infection after 72 h, all three
systems (2D, 3D Alvetex and 3D Invitrocue) provided for increasing infection levels, although variability
was higher in the 3D scaffolds compared to the 2D system. The Invitrocue scaffold showed both similar
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infection rates to the 2D assay, in contrast to the Alvetex scaffold which showed significantly lower
infection rates, and impaired formation of a multicell complex. This could be due to the smaller pore
size in the Alvetex scaffold (34–40 vs. 80–150 µM in Invitrocue) resulting in an increase in contact in the
latter between the scaffold and the peritoneal macrophage surface. The receptors responsible for cell
entry are arguably presented and localised better in the Invitrocue scaffold compared to the Alvetex one.
For this reason, subsequent experiments were conducted using only the Invitocue CelluSponge scaffold.
Although the only statistically significant differences in drug potencies between the 2D and 3D
in vitro infection models was seen when treating L. major infected macrophages with amphotericin B,
all of the EC50 values determined in the 2D and 3D assays are within the range of values reported in
the literature [54,55].
We used two methods to determine infection levels and drug activity in the 3D cultures:
(i) Invitrocue algorithm, and (ii) counting via Volocity software. Discerning the exact number of
parasites per peritoneal macrophage in a highly infected cell was difficult by normal light microscopy.
Using two algorithms we found that the Volocity algorithm was far more user driven and allowed for
user intervention to adjust the parameters and more accurately count the objects within the image.
For both types of analysis, the fluorescent signal from the individual parasites merged meaning it was
sometimes impossible to segment individual amastigotes. When the average parasite burden per host
cell was compared, it was evident that amphotericin B was more effective in clearing amastigotes in
contrast to miltefosine which was able to reduce the percentage of infected cells but with infected cells
showing a higher parasite burden. Future studies should use imaging equipment with higher level
of sensitivity.
Our results are similar to those seen in studies on other pathogens when the activity of compounds
was compared between 2D and 3D cell cultures. Bielecka et al. [56] tested anti-tuberculosis drugs in
2D and 3D systems and showed that whilst most compounds showed similar activities in the 3D and
2D cultures, there were a small number of compounds that showed different activities in 3D compared
to 2D assays. Cancer studies have also shown differences in sensitivity to drug exposure between cells
grown in 2D and 3D, for example, A431.H9 cells grown in 2D and 3D show differences in viability
when treated with the same concentrations of 5-fluorouracil and tirapazamine [57]. Another study [58]
showed that Her2+ breast cancer cell lines grown in 3D exhibited a lower susceptibility to doxorubicin
compared to 2D controls. Cells grown in 3D and then treated with tamoxifen were less susceptible to
the cytotoxic effects of the drug than cells grown in 2D. This research highlights the fact that cells in 3D
do not necessarily exhibit a higher drug susceptibility, but rather it is a combination of the specific
drug and the cellular environment that influences the experimental outcome.
4.3. The Potential for Use of iPSC Macrophages in Anti-Leishmanial Drug Assays
It has previously been shown that the type of macrophage used can significantly impact on drug
activity against intracellular Leishmania amastigotes [59,60]. Initially we established that all four cell
types we were investigating could maintain adequate levels of infection with L. major JISH, L. major
mCherry, L. amazonensis and L. mexicana species/strains. This is the first report that iPSC derived
macrophages have been shown to host a viable and dividing infection by a variety of Leishmania
species. It has been previously shown that iPSC derived macrophages and THP1 cells are both able
to phagocytose inert particles at similar rates [41]. One study [61] investigated differential gene
expression upon polarisation of all the four macrophages types used in our studies concluding that
the iPSC derived macrophages were most similar to the HBMM. The results of our experiments are
similar demonstrating that infection rates for IPSCs were most similar to HBMM. Spiller et al. [61]
also showed that the MBMM were the most different to the other cell types. This latter result was
not replicated in our studies where THP1 cells have the largest difference in response to Leishmania
parasites. Further confirmatory studies are required with normalized initial infections to overcome the
inoculum effect.
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Previous studies [59,60] using THP1 cells, human peripheral blood mononuclear cell derived
macrophages and mouse PEMs infected with L. donovani, showed that host cell type could have a
significant impact on the efficacy of standard anti-leishmanial drugs. We have now added iPSC cells to
this list of macrophage types showing that these respond to anti-leishmanial drugs in a similar fashion
to that observed in other cell types commonly used in in vitro assays [59]. Similar dose-response curves
and patterns in reduction of infection are seen in all cell types, when using the same parasite species.
The EC50 values obtained are similar to values reported in the literature [54,60,62].
Although iPSC derived macrophages are more difficult and expensive to obtain than cell lines,
they can be utilised in large scale assays whilst reducing the heterogeneity of macrophages obtained
from commercial sources from different donors. Compared to primary cells, their expansion potential is
a great advantage, but if not maintained correctly they can occasionally mutate into a cancer phenotype
due to their unrestricted growth cycle [63], caused by the addition of stem cell transcription factors.
The scientific literature on iPSCs, and more specifically iPSC derived macrophages, is relatively small
at present and none have made similar inter-macrophage comparisons. Our paper focuses on iPSC
derived macrophages as a pathogen infection model specifically showing that they can be infected by
Leishmania and respond to anti-leishmanial compounds as expected.
5. Conclusions
The Leishmania amastigote–macrophage model has been central to drug discovery assays for nearly
40 years, with modifications over the past decade to enable HCS which has driven the identification of
several novel anti-leishmanial compounds. Our approach to investigate the adaptability and predictivity
of the model to derive further important data other than compound potency has previously led to data
on the use of different macrophage populations [60], and rate of division of amastigotes [13], and here
adds to three other refinements—(i) culture media flow, (ii) 3D cell culture, and (iii) iPSC macrophages.
Although these refinements do not support the need for any radical change to routine assays, the media
flow system causes subtle differences in anti-leishmanial activities and offers opportunities for in vitro
PK/PD studies while the research around iPSC macrophages with the opportunity for genetic and
transcriptional analysis and modulation is only just beginning. The initial aim of our studies was to
determine whether these additional layers of complexity to in vitro assays would enable improved
prediction of in vivo activities in rodent models of infection. This was not achieved as some models
either proved to be complex and time consuming [42] or did not show significant difference to
established assays.
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